Rifaximin complexes
There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
1. A method of treating bowel disorders, the method comprising:
administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent, wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent.
2. The method of claim 1 , wherein the complex is a component of a tablet, a pellet, or a capsule.
3. The method of claim 1 , wherein the bowel disorder is travelers' diarrhea.
4. The method of claim 1 , wherein the bowel disorder is a bowel disease.
5. The method of claim 1 , wherein the bowel disorder is irritable bowel syndrome, Crohn's disease, chronic pancreatitis, pancreatic insufficiency and/or colitis.
6. The method of claim 1 , wherein the bowel disorder is microbe associated diarrhea.
7. The method according to claim 1 , wherein the ratio of rifaximin to complexing agent ranges from 20:1 to 1:20 w/w.
8. The method according to claim 1 , wherein the ratio of rifaximin to complexing agent ranges from 10:1 w/w to 1:2 w/w.
9. The method according to claim 1 , wherein the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
10. A method of treating bowel disorders, the method comprising:
administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
11. A method of treating bowel disorders, the method comprising:
administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is a bowel disease, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.
12. A method of treating bowel disorders, the method comprising:
administering to a patient a therapeutically effective amount of a complex comprising rifaximin and a complexing agent,
wherein the complex is in an amorphous form and exhibits enhanced solubility compared to a physical mixture of rifaximin and the complexing agent, the complex is a component of a tablet or a capsule, the bowel disorder is microbe associated diarrhea, and the rifaximin complex is administered with one or more pharmaceutically acceptable excipients.